Innate Pharma Stock (OTC:IPHYF), Trade Ideas

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Biotech

News

Penny Stocks

Health Care

General

IPHA

IPHYF

Innate Pharma To Stop COVID-19 Trial With Avdoralimab After Mid-Stage Study Disappoints

Innate Pharma&#39;s Lacutamab Shows Clinical Responses In KIR3DL2-Expressing Mycosis Fungoides Patients

Small Cap

Innate Pharma To Test Lacutamab In Relapsed/Refractory Peripheral T-Cell Lymphoma Patients

Innate Pharma SA

<ul>
<li>Innate Pharma SA&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ipha#NASDAQ">IPHA</a>) has announced its Phase 2 FORCE trial evaluating avdoralimab in COVID-19 patients with severe pneumonia&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/07/g21849885/update-on-avdoralimab-phase-2-force-trial-in-covid-19-patients-with-severe-pneumonia" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">did not meet its primary endpoints</a>&nbsp;in all three cohorts trial.</li>
<li>Based on these results, the Company will stop exploring avdoralimab in COVID-19.</li>
<li>The trial was initiated based on pre-clinical data showing that patients who progress towards severe COVID-19 disease exhibit activation of the C5a/C5aR1 pathway.&nbsp;</li>
<li>These translational data were observed in the trial; however, they did not translate into clinical benefit over best supportive care.</li>
<li>Investigators and the Independent Data Monitoring Committee observed slightly higher deaths in the treatment arm compared to placebo without establishing any causality.</li>
<li>Results from this trial, including translational data, are planned to be submitted for publication.</li>
<li>Price Action:&nbsp;IPHA shares closed at $3.52 on Friday.</li>
</ul>

<ul>
<li>Innate Pharma SA&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ipha#NASDAQ">IPHA</a>) has&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/06/g21660921/innate-pharma-presents-preliminary-data-from-tellomak-trial-showing-clinical-response-for-lacutama" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">announced preliminary data</a>&nbsp;from the mycosis fungoides (MF) cohort of the Phase 2 TELLOMAK clinical trial, evaluating lacutamab.</li>
<li>Data were shared at the International Conference on Malignant Lymphoma.</li>
<li>Lacutamab demonstrated clinical responses in patients with MF that express KIR3DL2 (cohort 2), reaching the pre-determined threshold to advance to stage 2.</li>
<li>As of May 10, data cutoff in the KIR3DL2-expressing cohort (n=17), complete (n=1), partial (n=3), and unconfirmed partial (n=2) global responses were observed.&nbsp;</li>
<li>Following the data cutoff, the two unconfirmed partial responses have been confirmed.</li>
<li>The company plans to initiate a peripheral T-cell lymphoma program for lacutamab. A Phase 1b monotherapy study is expected to start mid-year, and an investigator-sponsored combination study is expected in the second half of this year.</li>
<li>Lacutamab demonstrated a favorable safety profile. Mild-moderate treatment-related adverse events (AE) were observed, with one patient (out of 36) experiencing a severe AE.&nbsp;</li>
<li>No relevant skin toxicities were observed.</li>
<li>Innate will provide additional information on these results tomorrow in an investor event scheduled for 8:00 a.m. ET.&nbsp;</li>
<li>Price Action:&nbsp;IPHA shares are down 0.54% at $3.72 during the market session on the last check Tuesday.</li>
</ul>

Innate Pharma's Lacutamab Shows Clinical Responses In KIR3DL2-Expressing Mycosis Fungoides Patients

First data set from TELLOMAK establishes safety, clinical responses and skin improvement in patients with mycosis fungoides that express KIR3DL2 
&nbsp;
Data support continued development of lacutamab for KIR3DL2-expressing T-cell lymphomas
Results presented at 16th&nbsp;International Conference on Malignant Lymphoma; Innate to host investor event tomorrow, June 23, at&nbsp;2:00 p.m. CEST / 8:00 a.m. EDT
MARSEILLE, France, June 22, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/IPHYF#OTC">IPHYF</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) (&quot;Innate&quot; or the &quot;Company&quot;) today announced preliminary data from the mycosis fungoides (MF) cohort of the Phase 2 TELLOMAK clinical trial, evaluating lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody, in an oral presentation at the 16th&nbsp;International Conference on Malignant Lymphoma (16-ICML).
Lacutamab demonstrated clinical responses in patients with MF that express KIR3DL2 (cohort 2), reaching the pre-determined threshold to advance to stage 2.1
As of the May 10, 2021 data cutoff, in the KIR3DL2-expressing cohort (n=17), complete (n=1), partial (n=3) and unconfirmed partial (n=2) global responses were observed. Following the data cutoff, the two unconfirmed partial responses have been confirmed.
When evaluating responses in the skin, one patient had a complete response, eight patients had a partial response and two patients had an unconfirmed partial response. Out of seven patients with blood involvement, four had a complete response in the blood, and out of eight patients with lymph node involvement, one had a partial response. Following the data cutoff, the two unconfirmed partial responses in the skin have been confirmed.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
All patients (n=19) in the KIR3DL2-non-expressing cohort (Cohort 3) have been recruited. The threshold of responses needed to advance to stage 2 has not been reached, and follow up is ongoing.
&quot;We are pleased by the response demonstrated to date in patients with mycosis fungoides that express KIR3DL2, which has enabled us to advance this cohort earlier than expected,&quot;&nbsp;said&nbsp;Joyson Karakunnel, M.D., MSc, FACP, Chief Medical Officer of Innate Pharma. &quot;These data confirm our initial hypothesis that lacutamab may benefit patients with KIR3DL2-expressing T-cell lymphomas, and support our data-driven approach in pursuit of a new standard of care in this population. Looking ahead, we continue to enroll patients in both the mycosis fungoides and S&eacute;zary syndrome cohorts of our TELLOMAK study. In addition, we plan to initiate our peripheral T-cell lymphoma program for lacutamab, with our Phase 1b monotherapy study expected to start mid-year and an investigator-sponsored combination study expected in the second half of this year.&quot;
In line with previous observations, lacutamab demonstrated a favorable safety profile in MF. Grades 1-2 treatment-related adverse events (AE) were observed, with one patient (out of 36) experiencing a grade 3 AE. No relevant skin toxicities were observed.
&quot;Mycosis fungoides, and cutaneous T-cell lymphomas more broadly, are associated with poor clinical outcomes, particularly at advanced stages,&quot;&nbsp;said&nbsp;Pr. Martine Bagot,&nbsp;Head of the Dermatology Department, Saint Louis Hospital, Paris,&nbsp;and a study investigator.&nbsp;&quot;The clinical responses and favorable safety profile observed in the TELLOMAK study are quite encouraging so far. I am particularly pleased by the preliminary skin responses, as relapsed/refractory patients are in need of new treatment options that can improve their quality of life, and slow disease progression. I look forward to seeing more data from lacutamab as this trial progresses with the enrollment of additional patients in this cohort.&quot;
Innate will provide additional information on these results tomorrow, June 23, 2021, in an investor event scheduled for 2:00 p.m. CEST / 8:00 a.m. EDT. Details to access the live event are available in the investors section of Innate&#39;s website, where a replay of the webcast will also be archived for 90 days following the event.

Innate Pharma Highlights Presentation Of Preliminary Data from TELLOMAK Trial

Innate Pharma SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/IPHYF#OTC">IPHYF</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) (&quot;Innate&quot; or the &quot;Company&quot;) today announced that preliminary mycosis fungoides data from the Phase 2 TELLOMAK trial evaluating lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody in development for T-cell lymphomas, will be presented during an oral presentation at the virtual 16th&nbsp;International Conference on Malignant Lymphoma (16-ICML) taking place from June 18-22, 2021. 
&nbsp;
<table>
<tbody>
<tr>
<td>Oral presentation details:</td>
</tr>
<tr>
<td>Title:&nbsp;Lacutamab in patients with advanced mycosis fungoides according to KIR3DL2 expression: early results from the TELLOMAK phase 2 trial</td>
</tr>
<tr>
<td>Date and time:&nbsp;June 22, 2021 at 1 p.m. CEST</td>
</tr>
<tr>
<td>Abstract number:&nbsp;054</td>
</tr>
</tbody>
</table>
TELLOMAK trial investigator, Martine Bagot, M.D., Ph.D., Professor of Dermatology, Head of the Dermatology Department at the Saint-Louis Hospital, University of Paris, will deliver the oral presentation. 
&nbsp;
Pr. Bagot will also present the data during an Innate Pharma online webcast for the financial community on June 23, 2021. Details about this webcast will be provided on the Company website by June 16, 2021.

Innate Pharma To Present Data From Tellomak Trial At 16th International Conference on Malignant Lymphoma Jun. 22

<ul>
<li>Innate Pharma SA&#39;s&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/ipha#NASDAQ" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">IPHA</a>) ongoing&nbsp;<a class="editor-rtfLink" href="https://clinicaltrials.gov/ct2/show/NCT03902184" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">TELLOMAK Phase 2 trial</a>, evaluating lacutamab has reached the pre-determined number of responses needed to advance to stage 2, thus allowing Innate to recruit additional patients. The company expects to present the preliminary data from this cohort at a scientific meeting this year. The study is expected to recruit up to 150 patients.</li>
<li>Recruitment in cohort 3 is ongoing, evaluating lacutamab as monotherapy in KIR3DL2 non-expressing mycosis fungoides, the most common form of a type of blood cancer called cutaneous T-cell lymphoma.</li>
<li>The company also plans to&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/02/g19554724/innate-pharma-advances-lacutamab-clinical-development-program" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">initiate two parallel trials</a>&nbsp;to evaluate lacutamab in KIR3DL2-expressing patients with relapsed/refractory peripheral T-cell lymphoma, including a Company-sponsored Phase 1b trial to evaluate lacutamab as monotherapy in KIR3DL2-expressing patients with relapsed PTCL, and an investigator-sponsored trial to evaluate lacutamab in combination with chemotherapy GEMOX, versus GEMOX alone in KIR3DL2-expressing relapsed/refractory patients.</li>
<li>Webcast and conference call is scheduled for 8:00 a.m. ET today.</li>
<li>Price Action:&nbsp;IPHA shares closed 5.5% higher at $4.63 on Monday.</li>
</ul>

Innate Pharma SA ((Euronext Paris: IPH &amp;ndash, OTC:<a class="ticker" href="/stock/IPHYF#OTC">IPHYF</a>, NASDAQ:<a class="ticker" href="/stock/IPHA#NASDAQ">IPHA</a>) (&ldquo;Innate&rdquo; or the &ldquo;Company&rdquo;) today announced that the French National Agency for Medicines and Health Product Safety (ANSM) has agreed that the lacutamab (IPH4102) TELLOMAK Phase II trial can resume recruitment of new patients with relapsed/refractory S&eacute;zary syndrome and mycosis fungoides (MF) who have received at least two lines of prior systemic therapy.
Following discussions with the Company, the ANSM decision to allow new patient recruitment to resume in S&eacute;zary syndrome and MF in France is based on an assessment of the unmet medical need and the lack of currently available standard of care options.&nbsp;Conversely, because standard of care options are available to patients with peripheral T-cell lymphoma (PTCL), no new patients can enroll in the trial until a new Good Manufacturing Practice (GMP)-certified batch is available. However, currently enrolled PTCL patients can continue treatment in the trial.
In light of this feedback, the Company will take the operational measures to reactivate the lacutamab TELLOMAK trial in S&eacute;zary syndrome and MF in France and UK, where regulatory agencies have authorized it.&nbsp;

French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment In Sezary Syndrome And Mycosis Fungoides

INNATE PHARMA S.A. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/iphyf#OTC">IPHYF</a>) (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ipha#NASDAQ">IPHA</a>), a French biotechnology company focused on discovering, developing and commercializing first-in-class therapeutic antibodies designed to harness the immune system for the treatment of oncology indications with significant unmet medical need, today announced its intention to issue and sell, subject to market and other conditions, 10,666,666 of its ordinary shares in a global offering to specified categories of investors, comprised of an initial public offering of American Depositary Shares ("ADSs"), each representing one ordinary share, in the United States (the "U.S. Offering"), and a concurrent private placement of ordinary shares in Europe (including France) and other countries outside of the United States (the "European Private Placement," and together with the U.S. Offering, the "Global Offering").
Innate intends to grant the underwriters for the offering (the "Underwriters") a 30-day option to purchase additional ordinary shares (including in the form of ADSs) in an aggregate amount of up to 15% of the total number of ADSs and ordinary shares proposed to be sold in the Global Offering.
All securities to be sold in the Global Offering will be offered by Innate. Innate's ordinary shares are listed on Euronext Paris under the symbol "IPH". Innate has applied to list the ADSs to be sold in the U.S. Offering on theNasdaq Global Marketunder the ticker symbol "IPHA".
Citigroup Global Markets Inc., SVB Leerink LLC and Evercore Group LLC are acting as joint bookrunners for the U.S. offering and Citigroup is acting as global coordinator for the European private placement.
The offering price per ADS in U.S. dollars and the corresponding offering price per ordinary share in euros, as well as the final number of ADSs and ordinary shares sold in the Global Offering, will be determined following a bookbuilding process commencing immediately. The offering price per ADS and per ordinary share will be at least equal to the volume-weighted average (in the central order book excluding off-market block trades) of the closing prices of the Company's ordinary shares onEuronext Parisduring the last five stock market trading days preceding the determination of the offering price, potentially discounted by a maximum amount of 15%.
On an indicative basis, the completion of the Global Offering, assuming the issuance of 10,666,666 ordinary shares (including in the form of ADSs), would result in a dilution of approximately 14.3% of the Company's outstanding share capital on a non-diluted basis, and approximately 16.1% of the Company's outstanding share capital on a non-diluted basis in the event that the Underwriters exercise in full their option to purchase additional ordinary shares (including in the form of ADSs).
The ADSs and/or ordinary shares will be issued through a capital increase without shareholders' preferential subscription rights and for the benefit of a specified category of persons within the meaning of Article L.225-138 of the French Commercial Code (Code de commerce) and pursuant to the 31st and 32nd resolutions of the Company's combined general shareholders' meeting held on May 22, 2019. Under the authority granted by the shareholders in the 31st resolution, the ordinary shares and ADSs may only be purchased initially by industrial and commercial companies involved in the pharmaceutical/biotech sector or to investment companies, fund management companies or investment funds governed by French or foreign law or to any other legal person, including a trust, or natural person, investing in the pharmaceutical/ biotech sector, that is qualified to invest in a private placement. In order to purchase ordinary shares and/or ADSs in the Global Offering, potential investors will be required to execute and provide to the Underwriters an investor letter representing that they satisfy the foregoing investor criteria.
The closings of the U.S. Offering and the European Private Placement will occur simultaneously, will be conditioned on each other and are expected to occur on the third trading day after the final pricing and allocation of the Global Offering.
The Company expects to use the net proceeds from the Global Offering as follows (assuming an exchange rate of €1.00 = $1.0951, the exchange rate on October 3, 2019):
Approximately $30.0 million to advance the clinical development of the Company's lead product candidate, monalizumab, in collaboration with AstraZeneca, which is currently being evaluated for the treatment of patients with R/M SCCHN and in patients with advanced solid tumors, including CRC, to the end of the current Phase II program;
Approximately $55.0 million to advance the Phase II clinical development of IPH4102 through the first activity data for patients with Sézary syndrome, MF and PTCL;
Approximately $40.0 million to advance the Phase I/II clinical development of IPH5401 through the detection of activity signals in patients with solid tumors, including NSCLC, HCC and potentially other tumor types, as well as potentially in patients with inflammation disorders;
Approximately $30.0 million to build the Company's commercial capabilities for Lumoxiti in the United States and, if approved, in the European Union;
Approximately $55.0 million to expand and advance the Company's preclinical pipeline, including transitioning IPH5301 into clinical development; and
The remainder, if any, for working capital and general corporate purposes.

Offerings

IPOs

Innate Pharma Announces 10.6M ADS IPO @Price to be Determined Following Bookbuilding Process

Innate Pharma SA (OTC: <a class="ticker" href="https://www.benzinga.com/stock/iphyf#OTC">IPHYF</a>), today announced that AstraZeneca (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/azn#NYSE">AZN</a>) will advance monalizumab into a Phase III randomized clinical trial evaluating monalizumab in combination with cetuximab in patients suffering from recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), and the companies will co-fund the trial. The trial initiation is expected in 2020, subject to regulatory and compliance approvals.
"This is an important scientific milestone as we continue to invest in innovation and advance our late-stage clinical development pipeline," said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma. "Together with AstraZeneca, we are working diligently to progress this potential novel treatment for head and neck cancer patients, a population with a high unmet medical need."

Innate Pharma Announces  AstraZeneca to Advance Monalizumab to Phase III in Head and Neck Cancer

Sanofi (NYSE: <a class="ticker" href="/stock/sny#NYSE">SNY</a>) and Innate Pharma (OTC: <a class="ticker" href="/stock/iphyf#OTC">IPHYF</a>) today announced that they have entered into a research collaboration and licensing agreement to apply Innate Pharma's new proprietary technology to the development of innovative bispecific antibody formats engaging natural killer (NK) cells to kill tumor cells through the activating receptor NKp46.
	Sanofi and Innate Pharma will work together on the generation and evaluation of up to two bispecific NK cell engagers, using technology from Innate Pharma and Sanofi's proprietary bispecific antibody format as well as tumor targets. Under the terms of the licence agreement, Sanofi will be responsible for the development, manufacturing and commercialization of products resulting from the research collaboration. Innate Pharma will be eligible to up to €400m in development and commercial milestone payments as well as royalties on net sales.
	"Over the past year, Sanofi has launched strategic corporate collaborations in the field of immuno-oncology that exemplify our commitment to open innovation in R&amp;D and have the
 <a href="http://www.benzinga.com/pressreleases/16/01/g6129919/sanofi-and-innate-pharma-collaborate-on-new-bispecific-nk-cell-engagers">See full press release</a>

Contracts

Press Releases

Sanofi, Innate Pharma Collaborate on New Bispecific NK Cell Engagers in Immuno-Oncology

Innate Pharma (OTC: <a class="ticker" href="/stock/iphyf#OTC">IPHYF</a>) and OREGA Biotech today announce that they have entered into an exclusive licensing agreement by which OREGA Biotech grants Innate Pharma full worldwide rights to its program of first-in-class anti-CD39 checkpoint inhibitors. This license agreement arose from a fruitful research collaboration between the two companies initiated in 2014.
	CD39, initially discovered as a checkpoint inhibitor by OREGA Biotech's cofounder Dr.&nbsp;Armand Bensussan in collaboration with INSERM, is expressed on both regulatory T cells and tumor cells. It plays a major role in promoting immunosuppression through the pathway degrading adenosine triphosphate (ATP) into adenosine. Within the tumor microenvironment, ATP promotes immune cell-mediated killing of cancer cells. In contrast, adenosine accumulation causes immune suppression and dysregulation of immune cell infiltrates resulting in tumor spreading.
	Blockade of CD39 may therefore stimulate anti-tumor immunity across a wide range of tumors[1] by preventing the production of adenosine and by promoting the accumulation of
 <a href="http://www.benzinga.com/pressreleases/16/01/g6129816/innate-pharma-in-licenses-orega-biotechs-first-in-class-anti-cd39-check">See full press release</a>

Management

Innate Pharma in-licenses OREGA biotech's first-in-class anti-CD39 checkpoint inhibitor program

Innate Pharma SA (OTC: <a class="ticker" href="/stock/iphyf#OTC">IPHYF</a>) announces that a first patient has been dosed in the Phase I clinical trial of IPH4102 in patients with relapsed/refractory cutaneous T-cell lymphomas. IPH4102 is a first-in-class cytotoxic antibody against KIR3DL2, a tumor marker specifically expressed in most subtypes of CTCL. It has an orphan drug designation in the European Union for the treatment of CTCL.
	Pierre Dodion, Chief Medical Officer of Innate Pharma, said: "We are proud of and enthused by this major milestone for IPH4102, a program that was fully developed in house. The program has benefited from constant collaboration with Saint-Louis Hospital (Paris, France), and especially with Pr. Martine Bagot, Head of the Dermatology Department and co-discoverer with Pr. Armand Bensussan of the target KIR3DL2. Now, with the involvement of additional international expert centers in Europe and the USA, we believe that we are in optimal conditions to bring this exciting drug
 <a href="http://www.benzinga.com/pressreleases/15/12/g6017955/innate-pharma-first-patient-dosed-in-phase-i-trial-of-iph4102">See full press release</a>

Innate Pharma Announces First patient dosed in Phase I trial of IPH4102

Astrazeneca to make initial payment to Innate of $250M. Deal includes right for Innate to co-promote in Europe for 50% profit share in territory.

Astrazeneca, Innate Pharma Announce Global Co-Development and Commercialisation Collaboration for IPH2201 in Immuno-Oncology

Innate Pharma SA (OTC: <a class="ticker" href="/stock/iphyf#OTC">IPHYF</a>) today announced that it has signed a co-development and commercialization agreement with AstraZeneca (NYSE: <a class="ticker" href="/stock/azn#NYSE">AZN</a>), along with MedImmune, its global biologics research and development arm, to accelerate and broaden the development of Innate Pharma's proprietary anti-NKG2A antibody, IPH2201, including in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune. Currently in Phase II development, IPH2201 is a potential first-in-class humanized IgG4 antibody. NKG2A is a checkpoint receptor that inhibits the anti-cancer functions of Natural Killer (NK) and cytotoxic T-cells.
	The financial terms of the signed agreement include cash payments of up to $1.275 billion to Innate Pharma as well as double digit royalties on sales. The initial payment is $250 million, which includes a consideration for the exclusive global rights to AstraZeneca to co-develop and commercialize IPH2201 in combination with MEDI4736 and access to IPH2201 in monotherapy and other combinations in certain areas. AstraZeneca will pay to Innate a further $100 million prior to initiation of Phase III development, as well as additional regulatory and sales-related milestones of up to $925
 <a href="http://www.benzinga.com/pressreleases/15/04/g5439686/innate-pharma-and-astrazeneca-announce-global-agreement-for-iph2201-in-">See full press release</a>

Innate Pharma and AstraZeneca announce global agreement for IPH2201 in immuno-oncology

Innate Pharma SA (IPHYF) today announced that it has entered into a collaboration agreement with Sanofi (NYSE: <a class="ticker" href="/stock/sny#NYSE">SNY</a>) to apply Innate Pharma's site-specific conjugation technology to the development of new Antibody Drug Conjugates ("ADC").
	Hervé Brailly, CEO and co-founder of Innate Pharma, said: "We are very pleased to collaborate with Sanofi, a global healthcare leader. By combining some of Sanofi R&amp;D's anti-tumor antibodies with our novel technology for conjugating cytotoxic compounds, this collaboration opens the gate to next-generation ADCs with a potentially improved therapeutic index for patients with cancer".
	Sanofi-Aventis Recherche &amp; Développement, the French R&amp;D affiliate of Sanofi, will evaluate site-specific payload conjugation to enhance ADC pharmacokinetics, efficacy and safety and has the option to enter into a licencing agreement with Innate Pharma on this technology. Other terms of the agreement are undisclosed.
	About Innate Pharma's ADC technology: 
	Innate Pharma's innovative coupling technology uses bacterial transglutaminase (BTG) enzyme. It aims to address the heterogeneity associated with traditional ADC coupling technologies which limits the therapeutic index of antibody conjugates. With Innate Pharma's technology, a
 <a href="http://www.benzinga.com/pressreleases/15/04/g5412876/innate-pharma-and-sanofi-collaborate-on-next-generation-antibody-drug-c">See full press release</a>

Innate Pharma, Sanofi Announce Collaboration on Development of new Antibody Drug Conjugates

Innate Pharma SA (OTC: <a class="ticker" href="/stock/iphyf#OTC">IPHYF</a>) today announced that investigators from NCIC Clinical Trials Group presented the rationale and protocol of the Phase I/II trial of IPH2201, a first-in-class NKG2A checkpoint inhibitor, as a single agent in platinum resistant or sensitive patients with high grade ovarian cancer at the 13th International Congress on Targeted Anticancer Therapies ("TAT").
	NCIC CTG is sponsoring the study (known as IND.221) which will be conducted in Canada and enroll patients with ovarian cancer.&nbsp; In the first part of the study patients will receive IPH2201 at one of three dose levels. Thereafter 20 additional patients will be enrolled, in two groups, including patients whose ovarian cancer is felt to be either platinum sensitive or resistant.
	Pierre Dodion, Chief Medical Officer of Innate Pharma, said: "We are very pleased to work with NCIC CTG, a cooperative group of international reputation with extensive experience
 <a href="http://www.benzinga.com/pressreleases/15/03/g5307443/innate-pharma-collaborates-with-ncic-clinical-trials-group-on-the-phase">See full press release</a>

Innate Pharma Announces Investigators from NCIC CTG Presented Rationale, Protocol of IPH2201 Phase I/II Trial at TAT

Innate Pharma SA (OTC: <a class="ticker" href="/stock/iphyf#OTC">IPHYF</a>) today announced that the first Phase II trial of IPH2201, a first-in-class NKG2A checkpoint inhibitor, was opened at the Charité Comprehensive Cancer Center (CCCC), Berlin, Germany.
	IPH2201-201 is an open label Phase II trial testing IPH2201 as a single agent in a pre-operative setting of squamous cell carcinoma of the oral cavity (OCSCC), a tumor type representative of the larger group of squamous cell cancer of the head and neck.
	Dr Jan D Raguse, assistant medical director, Clinic for Oral &amp; Maxillofacial Surgery, Berlin Centre of Reconstructive Surgery, CCCC, and principal investigator of the study, said: "The rationale for this trial is based on the frequent expression of the NKG2A receptor and its ligand, HLA-E, in patients with OSCC". He added: "The pre-operative setting is very appealing as the absence of prior therapy eliminates confounding effects. This design optimizes our ability to evaluate the antitumor activity of IPH2201. Access to the tumor is another key attractive feature of the study as it will allow a detailed pharmacological evaluation".
	Hervé Brailly, CEO
 <a href="http://www.benzinga.com/pressreleases/14/12/g5095276/innate-pharma-first-phase-ii-trial-with-iph2201-open-in-head-and-neck-c">See full press release</a>

Innate Pharma Announces First Phase II Trial with IPH2201 Open in Head and Neck Cancer

Innate Pharma (OTC: <a class="ticker" href="/stock/iphyf#OTC">IPHYF</a>) today announced the start of the cohort expansion portion of the Phase I clinical trial testing the combination of the two investigational checkpoint inhibitors lirilumab (anti-KIR) and nivolumab (anti-PD-1) in selected solid tumors.
	Lirilumab is licensed to Bristol-Myers Squibb Company (NYSE: <a class="ticker" href="/stock/bmy#NYSE">BMY</a>) and this Phase I trial is being conducted by Bristol-Myers Squibb.
	About the Phase I trial with lirilumab (anti-KIR checkpoint inhibitor; BMS-986015) in combination with nivolumab (anti-PD-1 checkpoint inhibitor BMS-936558) in solid tumors: 
 <a href="http://www.benzinga.com/pressreleases/14/03/g4430165/innate-pharma-start-of-cohort-expansion-of-phase-i-trial-with-lirilumab">See full press release</a>

Global

Innate Pharma Announces Bristol-Myers Squibb Conducting Phase I Trial with Lirilumab and Nivolumab in Selected Solid Tumors 

Innate Pharma (OTC: <a class="ticker" href="/stock/iphyf#OTC">IPHYF</a>) announces today the completion of a private placement directed to US-based specialist institutional investors. The gross amount raised is €20.3 million corresponding to 7.6 million new ordinary shares which will be issued. The subscription price of each new share is €2.67, which was the volume-weighted- average-price of the previous three trading sessions preceding the closing of the private placement on November 19, 2013 and a 4% discount on the closing price on November 15, 2013, the trading day before the announcement of the launching of the offering. The capital increase was placed entirely with US-based institutional investors specializing in the sector including funds managed by QVT Financial LP and Redmile Group. Through this offering, OrbiMed acquired more than 5% of the share capital of Innate Pharma. Hervé Brailly, CEO, said: «&nbsp;This fundraising is a resounding success: we have built a strong shareholder base in the United States, the most important capital market for biotech companies. We now have more than 25% of Innate Pharma's share capital held
 <a href="http://www.benzinga.com/pressreleases/13/11/tr4093993/innate-pharma-raises-20-3-million-in-a-private-placement-subscribed-en">See full press release</a>

Guidance

Financing

Asset Sales

Innate Pharma Raises €20.3M in Private Placement

Innate Pharma SA (OTC: <a class="ticker" href="/stock/iphyf#OTC">IPHYF</a>) announces the initiation of a new program to develop an anti-MICA therapeutic antibody in oncology. The program, named IPH43, is the newest to emerge from Innate Pharma's discovery platform.
	MICA is a highly polymorphic ligand of the NK cell activating receptor NKG2D. MICA is specifically expressed&hellip;Innate Pharma SA (OTC: <a class="ticker" href="/stock/iphyf#OTC">IPHYF</a>) announces the initiation of a new program to develop an anti-MICA therapeutic antibody in oncology. The program, named IPH43, is the newest to emerge from Innate Pharma's discovery platform.
	MICA is a highly polymorphic ligand of the NK cell activating receptor NKG2D. MICA is specifically expressed on several highly prevalent solid tumors including breast, colorectal and lung. Innate Pharma has generated a panel of high affinity antibodies recognizing all forms of MICA which is now being tested and optimized to select the best development candidate.
	Nicolai Wagtmann, CSO of Innate Pharma, said: "MICA's very clean expression profile on tumor cells and not healthy cells makes it an exciting target for cancer. Like with lirilumab, we successfully generated antibodies overcoming target polymorphism, which is a major challenge and a pre-requisite for development. We now look forward to applying our state-of-the-art immunopharmacology and antibody-engineering platforms to further advance
 <a href="http://www.benzinga.com/pressreleases/13/11/g4082944/innate-pharma-initiates-iph43-program-to-develop-first-in-class-anti-mi">See full press release</a>

Innate Pharma Initiates Iph43 Program to Develop First-In-Class Anti-Mica Antibody

Innate Pharma S.A. (IPHA) Q4 2023 Earnings Call Transcript

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Innate Pharma (IPHA – Research Report) today and set a price target of $1...

Innate Pharma: A Strong Buy on Promising Clinical Progress and Solid Financials

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Innate Pharma SA (IPHYF – Research Report), Medios...

Analysts Offer Insights on Healthcare Companies: Innate Pharma SA (OtherIPHYF), Medios AG (OtherMEDOF) and Tecan Group AG (OtherTCHBF)

Goldman Sachs analyst Rajan Sharma has maintained their neutral stance on IPHYF stock, giving a Hold rating on March 21. Rajan Sharma has given his...

Innate Pharma SA: A Balanced Hold Rating Amidst Clinical Setbacks and Cautious Optimism

Innate Pharma S.A. (IPHYF) has disclosed a new risk, in the Employment / Personnel category. Innate Pharma S.A. faces significant business risk as ...

Innate Pharma's Growth at Risk: The Challenge of Relying on External Partners and a Lean Team

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Innate Pharma (IPHA – Research Report) and keeping the price target ...

Innate Pharma: A Strong Buy on IPH45's Promising Data and Solid Financial Projections

Innate Pharma S.A. (FR:IPH) has released an update. Innate Pharma S.A. announced the progression of the NK cell engager SAR443579 / IPH6101, develo...

Innate Pharma's NK Cell Engager Enters Phase 2 Trials

Innate Pharma S.A. (FR:IPH) has released an update. Innate Pharma S.A., a clinical-stage biotechnology company, has announced its Annual General Me...

Innate Pharma Announces Upcoming Annual General Meeting

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on IPHA stock, giving a Buy rating on April 11. Daina Graybosch has gi...

Buy Rating Affirmed for Innate Pharma Amidst Promising Platforms and Strategic Growth Potential

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Qiagen (QGEN – Research Report), Innate Pharma SA (IPHYF – Resear...